# HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

> **NCT06769425** · PHASE1 · RECRUITING · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 157 (estimated)

## Conditions studied

- Recurrent Ovarian Cancer
- HER2-negative
- Advanced Breast Cancer
- TNBC
- Advanced Prostate Cancer
- Advanced Gastric Cancer

## Interventions

- **DRUG:** HS-10502 + NHA
- **DRUG:** HS-10502 + HS-20093
- **DRUG:** HS-10502+ Apatinib
- **DRUG:** HS-10502 + HS-20089
- **DRUG:** HS-10502 + Platinum + Bevacizumab
- **DRUG:** HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan
- **DRUG:** HS-10502 + Bevacizumab

## Key facts

- **NCT ID:** NCT06769425
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-07
- **Primary completion:** 2026-05-07
- **Final completion:** 2026-08-31
- **Target enrollment:** 157 (ESTIMATED)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06769425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06769425, "HS-10502 Combination Treatment in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06769425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*